SCHEMBL21909899

SCHEMBL21909899

COc1ccc(C(=O)O)cc1-c1ccc2nc(C)ncc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.50
PDGFRA P16234 2/20 0.50
PLG P00747 1/20 0.49
PLAU P00749 1/20 0.49
LMNA P02545 2/20 0.46
RARA P10276 2/20 0.44
RARB P10826 2/20 0.44
RARG P13631 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
TPMT P51580 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21909897 0.89 CHEK2 (0.46) PDGFRBPDGFRAPLGPLAUMAPK1
SCHEMBL3566203 0.80 TDP1 (0.54) LMNARAB9AKDM4EALDH1A1GAA
SCHEMBL6244003 0.76 CA12 (0.71) PLGPLAULMNARARARARB
SCHEMBL8888494 0.76 RARA (0.58) PLGPLAULMNARARARARB
SCHEMBL5504803 0.73 MAPK14 (0.55) BRAFABL1
SCHEMBL5488850 0.73 LCK (0.62) BRAFABL1
SCHEMBL17559287 0.72 AR (0.61) PLGPLAULMNARARARARB
SCHEMBL6248649 0.72 LMNA (0.59) PLGPLAULMNARARARARB
SCHEMBL6248458 0.72 LMNA (0.68) LMNARARARARBRARGCA12
SCHEMBL3205541 0.72 LMNA (0.59) LMNARARARARBRARGCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2020-12-29 US disclosed
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2020-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 PDGFRB 11/4885PDGFRA 15/4885PLG 1144/4885
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 PDGFRB 11/4885PDGFRA 15/4885PLG 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.